Qulipta

AAN 2023: AbbVie highlights Qulipta’s edge over oral migraine prophylaxis
AAN 2023: AbbVie highlights Qulipta’s edge over oral migraine prophylaxis
Clinical Trials Arena
AbbVie
Qulipta
chronic migraine
Flag link:
FDA expands Qulipta indication to include chronic migraine prevention
FDA expands Qulipta indication to include chronic migraine prevention
Healio
AbbVie
migraine
FDA
CGRP blockers
Qulipta
Flag link:
AbbVie files Qulipta for chronic migraine prevention
AbbVie files Qulipta for chronic migraine prevention
Pharmaforum
AbbVie
Qulipta
migraines
FDA
Flag link:
AbbVie touts Qulipta chronic migraine win as Biohaven duel heats up
AbbVie touts Qulipta chronic migraine win as Biohaven duel heats up
Fierce Pharma
AbbVie
Biohaven
migraines
Qulipta
Nurtec
Flag link:
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
Fierce Pharma
AbbVie
pharma marketing
migraines
Qulipta
television ads
DTC ads
Flag link:
AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
Fierce Pharma
AbbVie
Biohaven
migraines
Qulipta
Nurtec ODT
Flag link:
AbbVie’s Qulipta Set to Become Blockbuster in the Migraine Market
AbbVie’s Qulipta Set to Become Blockbuster in the Migraine Market
Clinical Trials Arena
AbbVie
Qulipta
migraines
FDA
Flag link:
AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug
AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug
Endpoints
AbbVie
Qulipta
migraines
Allergan
Biohaven
FDA
Flag link: